Skip Navigation


Schizophrenia Bulletin Advance Access originally published online on January 16, 2008
Schizophrenia Bulletin 2008 34(2):302-309; doi:10.1093/schbul/sbm143
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
34/2/302    most recent
sbm143v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kane, J. M.
Right arrow Articles by Leucht, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kane, J. M.
Right arrow Articles by Leucht, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.

Unanswered Questions in Schizophrenia Clinical Trials

John M. Kane1,2,3 and Stefan Leucht4
2 The Zucker Hillside Hospital, Glen Oaks, New York, NY
3 The Albert Einstein College of Medicine, Bronx, New York, NY
4 Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany

Keywords: schizophrenia / clinical trials / psychopharmacology

The first 150 words of the full text of this article appear below.

The treatment of schizophrenia remains an enormous challenge. Patients with this illness present with a wide variety of signs and symptoms. Response to treatment and illness course vary considerably. At the same time, we do not have the benefit of established neuropathological, neurophysiological, or neurochemical measures to inform phenotypic classification, and as a result we rely on the clinical evaluation of an array of signs and reports of subjective experience in order to establish diagnoses. The care and thoroughness with which the differential diagnostic process is carried out varies enormously from one clinical setting to another and from clinical practice to clinical research. In addition, mental health care is fragmented, and records are often poor or not readily obtainable and as a result gathering an accurate history of previous symptoms, course, treatments utilized, and response (either therapeutic or adverse) can be very difficult. Patients are not generally in a position . . . [Full Text of this Article]


   Choice of Drug
 

   Optimum Dose
 

   How Should Clinicians Measure Response?
 

   How Long Should a Trial of an Antipsychotic be Before it is Viewed as Ineffective?
 

   What Medications Are Most Effective in Treating Severe Agitation?
 

   How Many Treatments Should be Tried Before Initiating a Trial of Clozapine in Treatment Refractory or Poorly Responsive Patients?
 

   Is Polypharmacy Helpful?
 

   What is the Appropriate Duration of Maintenance Treatment in First-Episode Patients?
 

   Can and How Much Should Antipsychotic Dose be Reduced in the Maintenance Phase of Treatment?
 

   To What Extent Can Long-Acting Injectable Medication Reduce Rates of Relapse and Rehospitalization Compared to Usual Care?
 

   How Should Patients Who Relapse Despite Adequate Dosages and Adherence to Medication be Treated?
 

   What is The Best Way to Manage Sleep Abnormalities in Schizophrenia?
 

   How Best Should Negative Symptoms be Treated?
 

   Challenges in the Conduct of Clinical Trials
 

   Conclusions
 
1 To whom correspondence should be addressed; tel: 718 470-8141, fax: 718 343-7739, e-mail: psychiatry@lij.edu.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?